{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:56:37Z","timestamp":1792439797988,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016058","name":"Stichting Lymph&Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012200","name":"Laffey-McHugh Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37-CA-262362-02"],"award-info":[{"award-number":["R37-CA-262362-02"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ccell.2025.01.013","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T10:43:33Z","timestamp":1740048213000},"page":"537-551.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["EZH1\/EZH2 inhibition enhances adoptive T\u00a0cell immunotherapy against multiple cancer models"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-7482","authenticated-orcid":false,"given":"Patrizia","family":"Porazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siena","family":"Nason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Carturan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ghilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneeth","family":"Guruprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka Anant","family":"Padmanabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Fardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymone","family":"Pajarillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ositadimma","family":"Ugwuanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devora","family":"Delman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew G.","family":"Angelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Shestova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Isshiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"B\u00e9guelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari M.","family":"Melnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald P.","family":"Linette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Beatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz M.","family":"Carreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Paruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2025.01.013_bib1","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2025.01.013_bib2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ccell.2025.01.013_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2025.01.013_bib4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2025.01.013_bib5","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.01.013_bib6","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","article-title":"Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors","volume":"14","author":"Schoenfeld","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2025.01.013_bib7","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2025.01.013_bib8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2353\/ajpath.2009.081142","article-title":"Epigenetic dysregulation in cancer","volume":"175","author":"Muntean","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ccell.2025.01.013_bib9","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.18632\/oncotarget.6198","article-title":"EZH2 in normal hematopoiesis and hematological malignancies","volume":"7","author":"Herviou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ccell.2025.01.013_bib10","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41568-020-0288-4","article-title":"The epigenomics of sarcoma","volume":"20","author":"Nacev","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2025.01.013_bib11","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/ijc.33727","article-title":"Exploiting epigenetic dependencies in ovarian cancer therapy","volume":"149","author":"Coughlan","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ccell.2025.01.013_bib12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.urolonc.2023.03.005","article-title":"Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential","volume":"41","author":"Ragavi","year":"2023","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ccell.2025.01.013_bib13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41591-019-0376-8","article-title":"Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer","volume":"25","author":"Mohammad","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.01.013_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","article-title":"Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise","volume":"17","author":"Morel","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.01.013_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ccell.2025.01.013_bib16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2025.01.013_bib17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2025.01.013_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2025.01.013_bib19","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1182\/blood-2010-04-280149","article-title":"EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis","volume":"116","author":"Velichutina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.01.013_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ccell.2025.01.013_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/13543776.2021.1841167","article-title":"Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)","volume":"31","author":"Dockerill","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ccell.2025.01.013_bib22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/0008-5472.CAN-21-1297","article-title":"Targeting Chemotherapy to Decondensed H3K27me3-Marked Chromatin of AML Cells Enhances Leukemia Suppression","volume":"82","author":"Porazzi","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2025.01.013_bib23","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ccell.2020.04.004","article-title":"Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response","volume":"37","author":"Beguelin","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2025.01.013_bib24","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2025.01.013_bib25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.immuni.2020.11.002","article-title":"Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas","volume":"54","author":"Dersh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2025.01.013_bib26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2025.01.013_bib27","article-title":"Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies","volume":"9","author":"Serganova","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ccell.2025.01.013_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13148-021-01046-0","article-title":"Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy","volume":"13","author":"Lodewijk","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.ccell.2025.01.013_bib29","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","article-title":"EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer","volume":"22","author":"Bracken","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.ccell.2025.01.013_bib30","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2025.01.013_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1741-7015-9-63","article-title":"Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications","volume":"9","author":"Ciarapica","year":"2011","journal-title":"BMC Med."},{"key":"10.1016\/j.ccell.2025.01.013_bib32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1535-7163.MCT-17-0437","article-title":"Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer","volume":"17","author":"Jones","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2025.01.013_bib33","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s43018-021-00185-w","article-title":"EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer","volume":"2","author":"Morel","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ccell.2025.01.013_bib34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2008.10.016","article-title":"EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency","volume":"32","author":"Shen","year":"2008","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ccell.2025.01.013_bib35","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.stem.2012.08.001","article-title":"Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest","volume":"11","author":"Hidalgo","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ccell.2025.01.013_bib36","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","article-title":"Enhancer of zeste homolog 2 (EZH2) inhibitors","volume":"59","author":"Gulati","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ccell.2025.01.013_bib37","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2025.01.013_bib38","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.01.013_bib39","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-017-01029-x","article-title":"EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop","volume":"8","author":"Beguelin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2025.01.013_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molimm.2020.01.006","article-title":"EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas","volume":"119","author":"Otsuka","year":"2020","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ccell.2025.01.013_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T\u00a0cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ccell.2025.01.013_bib42","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T\u00a0cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2025.01.013_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02486","article-title":"Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology","volume":"9","author":"Watanabe","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ccell.2025.01.013_bib44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3389\/fimmu.2018.00549","article-title":"Ezh2 Regulates Activation-Induced CD8(+) T Cell Cycle Progression via Repressing Cdkn2a and Cdkn1c Expression","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ccell.2025.01.013_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ccell.2025.01.013_bib46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","article-title":"EZH2 inhibition enhances T\u00a0cell immunotherapies by inducing lymphoma immunogenicity and improving T\u00a0cell function","volume":"43","author":"Isshiki","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2025.01.013_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-24-0089","article-title":"Transient EZH2 suppression by Tazemetostat during in\u00a0vitro expansion maintains T-cell stemness and improves adoptive T-cell therapy","volume":"13","author":"Hou","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2025.01.013_bib48","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","article-title":"Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy","volume":"11","author":"Chen","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2025.01.013_bib49","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1038\/s41467-019-12464-3","article-title":"Single-cell transcriptomics of human T\u00a0cells reveals tissue and activation signatures in health and disease","volume":"10","author":"Szabo","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2025.01.013_bib50","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.01.013_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/epigenomes2030016","article-title":"Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity","volume":"2","author":"Alzrigat","year":"2018","journal-title":"Epigenomes"},{"key":"10.1016\/j.ccell.2025.01.013_bib52","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2014-06-581082","article-title":"Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia","volume":"125","author":"Xu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.01.013_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110971","article-title":"Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1","volume":"39","author":"Deng","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ccell.2025.01.013_bib54","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ccell.2025.01.013_bib55","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1084\/jem.20170084","article-title":"Signaling function of PRC2 is essential for TCR-driven T\u00a0cell responses","volume":"215","author":"Dobenecker","year":"2018","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2025.01.013_bib56","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.stem.2022.06.014","article-title":"EZH1 repression generates mature iPSC-derived CAR T\u00a0cells with enhanced antitumor activity","volume":"29","author":"Jing","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ccell.2025.01.013_bib57","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.4049\/jimmunol.165.6.3043","article-title":"The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion","volume":"165","author":"Gramaglia","year":"2000","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2025.01.013_bib58","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3324\/haematol.2019.231183","article-title":"CD28.OX40 co-stimulatory combination is associated with long in\u00a0vivo persistence and high activity of CAR.CD30 T-cells","volume":"106","author":"Guercio","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ccell.2025.01.013_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1200914","article-title":"ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype","volume":"13","author":"Moreno-Cortes","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ccell.2025.01.013_bib60","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s00262-022-03193-6","article-title":"CXCL9-modified CAR T\u00a0cells improve immune cell infiltration and antitumor efficacy","volume":"71","author":"Tian","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ccell.2025.01.013_bib61","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/0008-5472.CAN-15-1938","article-title":"PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer","volume":"76","author":"Nagarsheth","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2025.01.013_bib62","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2025.01.013_bib63","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.01.013_bib64","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1038\/s41467-020-18298-8","article-title":"Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8(+) T\u00a0cell exhaustion","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2025.01.013_bib65","article-title":"Beyond the blood: expanding CAR T cell therapy to solid tumors","author":"Uslu","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2025.01.013_bib66","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2019000847","article-title":"The immune landscape and response to immune checkpoint blockade therapy in lymphoma","volume":"135","author":"Kline","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2025.01.013_bib67","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","article-title":"Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity","volume":"23","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ccell.2025.01.013_bib68","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1172\/JCI99760","article-title":"Modulation of EZH2 expression in T\u00a0cells improves efficacy of anti-CTLA-4 therapy","volume":"128","author":"Goswami","year":"2018","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.ccell.2025.01.013_bib69","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S1470-2045(24)00502-3","article-title":"Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study","volume":"25","author":"Maruyama","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2025.01.013_bib70","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","article-title":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study","volume":"25","author":"Zinzani","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2025.01.013_bib71","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41587-021-00902-x","article-title":"Profiling the genetic determinants of chromatin accessibility with scalable single-cell CRISPR screens","volume":"39","author":"Liscovitch-Brauer","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2025.01.013_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ccell.2025.01.013_bib73","doi-asserted-by":"crossref","first-page":"25764","DOI":"10.18632\/oncotarget.25359","article-title":"Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T\u00a0cell immunotherapy of multiple myeloma","volume":"9","author":"Bu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ccell.2025.01.013_bib74","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T\u00a0cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2025.01.013_bib75","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2025.01.013_bib76","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T\u00a0cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.01.013_bib77","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2025.01.013_bib78","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2025.01.013_bib79","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ccell.2025.01.013_bib80","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2025.01.013_bib81","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1158\/2159-8290.CD-21-1026","article-title":"Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2025.01.013_bib82","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1038\/s41467-021-24562-2","article-title":"Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting","volume":"12","author":"Bear","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2025.01.013_bib83","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2025.01.013_bib84","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2025.01.013_bib85","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610825000315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610825000315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:39:27Z","timestamp":1773157167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825000315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1535610825000315"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2025.01.013","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EZH1\/EZH2 inhibition enhances adoptive T\u00a0cell immunotherapy against multiple cancer models","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2025.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}